JCJean K Carr

Jean K Carr

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jean K Carr has a total of 32 co-authors. Here are the top co-authors by number of shared publications:

  • Lindsay M Eyzaguirre

    Department of Epidemiology, Institute of Human Virology, University of Maryland Biotechnology Institute, 725 West Lombard Street, Baltimore, MD 21201, USA

    2 shared publications
  • Maria Mercedes Avila

    Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS, UBA CONICET) , Buenos Aires, Argentina

    2 shared publications
  • Silvia M Montano

    US Naval Medical Research Center Detachment (NMRCD). Unit 3800, APO-AA 34031-3800, Lima, Peru

    2 shared publications
  • Ana Ceballos

    National Reference Center for AIDS, Department of Microbiology, University of Buenos Aires School of Medicine, Buenos Aires, Argentina

    1 shared publication
  • Boulos A Botros

    From the US Military HIV Research Program, Walter Reed Army Institute of Research, and the Henry M. Jackson Foundation for the Advancement of Military Medicine, Rockville, MD; †National AIDS Prevention Center, Almaty, Kazakhstan; and the ‡US Naval Medical Research Unit, No. 3, Cairo, Egypt

    1 shared publication
  • Christian T. Bautista

    Walter Reed Army Institute of Research, Silver Spring, MD, USA

    1 shared publication

Latest Publications

  • Open Access

    Genetic Characterization of HIV-1 Strains Circulating in Kazakhstan

    by Lindsay M Bs Eyzaguirre, Isidora B Erasilova, Yuka Nadai, Magdi D Dvm Saad, Natalya G Kovtunenko, Peter J Gomatos, Victoria V Zeman, Boulos A Botros, Jose L Sanchez, Deborah L Birx, et al.

    To determine the HIV-1 genetic diversity in Kazakhstan, 85 blood samples from HIV-seropositive donors were collected between 2001 and 2003. The study population consisted of 91.8% injecting drug users (IDUs); the remainder was infected sexually or iatrogenically. A genomic region that included part of the polymerase gene was sequenced for all 85 samples, and from these, 6 samples were randomly selected for nearly full genome sequencing. Subtype A was the most common genetic form (94.1%), followed by CRF02_AG (4.7%) and subtype C (1.2%). All subtype A sequences clustered closely with samples from countries of the former Soviet Union (FSU). From these sequences, 47 (58.8%) presented the secondary protease inhibitor mutation V77I that has been linked to a genetic lineage in the FSU epidemic. In addition, most had the other 2 mutations that characterize the “V77I haplotype.” All 6 nearly full-length sequences were subtype A and clustered with other FSU strains. The CRF02_AG strains from this population clustered with strains from Uzbekistan, reflecting the spread of the CRF02_AG epidemic in Central Asia. The HIV epidemic in Kazakhstan is predominantly in IDUs and is indigenous to the geographic region, and most of the strains are genetically similar to those circulating in the FSU and other parts of Central Asia.


  • First Molecular Surveillance Report of HIV Type 1 in Injecting Drug Users And Female Sex Workers along The U.S.–Mexico Border

    by L. Eyzaguirre, K.C. Brouwer, Y. Nadai, T.L. Patterson, R. Ramos, M. Firestone Cruz, P. Orozovich, S.A. Strathdee, J.K. Carr

    HIV prevalence is increasing among high-risk populations in the Mexican–U.S. border cities of Tijuana and Ciudad Juarez. In 2005, the molecular epidemiology of HIV-1 was studied among injecting drug users (IDU) and female sex workers (FSW) in these cities, which are corridors for over two-thirds of the migrant flow between Mexico and the United States. Eleven samples (eight IDU and three FSW) were successfully amplified, sequenced, and analyzed. The results revealed that all 11 samples were subtype B. There was no phylogenetic clustering or separation of the strains between IDU and FSW or between Tijuana and Ciudad Juarez nor was the Mexican strain phylogenetically distinct from other subtype B strains. Two of three drug naive FSWs had low-level HIV-1 resistance mutations. This community-based study demonstrated that HIV-positive IDUs and FSWs in Ciudad Juarez and Tijuana were predominantly infected with subtype B. Further prevalence studies on HIV-1 resistance mutations among FSWs in these border cities are warranted.


  • Open Access

    High genetic variability of HIV-1 in female sex workers from Argentina

    by María A Pando, Lindsay M Eyzaguirre, Gladys Carrion, Silvia M Montano, José L Sanchez, Jean K Carr, María M Avila

    A cross-sectional study on 625 Female Sex Workers (FSWs) was conducted between 2000 and 2002 in 6 cities in Argentina. This study describes the genetic diversity and the resistance profile of the HIV-infected subjects.


  • Open Access

    First report of an HIV-1 triple recombinant of subtypes B, C and F in Buenos Aires, Argentina

    by María A Pando, Lindsay M Eyzaguirre, Marcela Segura, Christian T Bautista, Rubén Marone, Ana Ceballos, Silvia M Montano, José L Sánchez, Mercedes Weissenbacher, María M Ávila, et al.


  • Viral diversity as a challenge to HIV-1 vaccine development

    by Jean K Carr

    This review attempts to acquaint the reader with the molecular epidemiology of HIV-1 and to describe some of the more promising approaches to vaccine development in the light of this diversity. The primary genetic forms of HIV-1 in the world today are subtypes A, B, C, CRF01-AE and CRF02-AG. In sub-Saharan Africa, subtypes A and C and CRF02-AG account for most of the infections. In Asia, there are subtypes B, C and CRF01 AE. Europe, the Americas and the Caribbean are dominated by subtype B, and subtype A is in the former Soviet Union. While the genetic diversity of HIV-1 in the world can seem daunting, the vast majority of infections are actually caused by one of these five genetic forms. Approaches to dealing with this in the development of vaccines include targeting conserved regions of the genome, creating ancestral forms of the virus or putting many different forms together into a cocktail. Each of these approaches shows promise. To optimize the chances of initially showing efficacy in HIV vaccine trials, the genetic form of the vaccine strains will resemble those of the circulating strains in the target population. Once efficacy is demonstrated, however, it will be possible to determine whether genetic subtype is at all predictive of vaccine protection. Although the genetic diversity of HIV-1 is impressive, it is not limitless. Most of the infections worldwide are actually due to a handful of strains. It should be possible for a few vaccine strategies to conquer HIV-1 definitively.